Pediatrics, Pediatric Hematology-Oncology · Las Vegas, NV
NPI
1821312844
Since 2010
Specialty
Pediatrics, Pediatric Hematology-Oncology
Code 2080P0207X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
1 Breakthrough Way
Las Vegas, NV, 89135
Phone (702) 732-1493
Groups this clinician bills Medicare through
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$531K
24 prescriptions
Company payments, 2025
$24K
From 17 companies
Medicare prescription drug claims, 2024
In 2024, the drug Aimee M Foord prescribed most often to Medicare patients was Cerezyme (Imiglucerase), with 11 prescriptions and refills. In total Aimee M Foord wrote 24 Medicare prescriptions that cost $531K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-11-05.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Cerezyme Imiglucerase | 11 | 11 | Under 11 | $529K |
Brand drugs: 14 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Aimee M Foord $24K ($24K in general payments such as food, travel and fees) from 17 companies. The largest payer was Genzyme Corporation with $9,277.
| Company | Payments | Amount |
|---|---|---|
| Genzyme Corporation SNY | 7 | $9,277 |
| Sobi, Inc SOBI.ST | 4 | $6,427 |
| CSL Behring CSL.AX | 14 | $5,892 |
| Novo Nordisk Inc NVO | 3 | $2,019 |
| Kedrion Biopharma, Inc. | 2 | $142 |
| Pharming Healthcare, Inc. | 1 | $123 |
| Incyte Corporation INCY | 2 | $41.42 |
| Chiesi USA, Inc. | 1 | $34.7 |
| Uswm, LLC | 1 | $31.16 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $30.29 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.